BioPacific Conference 2009 Agenda

Theme: Challenges and Opportunities in the U.S. and China: Through the Global Downturn and Beyond

Plenary Session: Successes, Challenges and
Opportunities of the Biotech Industry

  • Norbert Bischofberger, Ph.D. (Executive Vice President & Chief
    Scientific Officer, Gilead Sciences): “Gilead Sciences: The Evolution
    of HIV Treatment and Gilead’s Contributions”

  • Nancy Chang, Ph.D. (Chairman and Managing Director, Caduceus Asia
    partner Fund, OrbiMed Venture; Founder of Tanox): “Changing Nature of
    Pharma R&D and Outsourcing Environment in Asia”

  • Karl Sanford, Ph.D. (Vice President Technology, Genencor): “Recent
    Developments in Industrial Biotechnology: From Industrial Enzymes to
    Biochemicals to Biofuels”

Scientific Session: Advances in Oncology and
Neuroscience R&D

  • Ira Mellman, Ph.D. (Vice President, Research Oncology, Genentech):
    “Oncology Research at Genentech: Where Basic Science Needs No

  • Peter Lamb, Ph.D. (Chief Scientific Officer, Exelixis): “Discovery
    and Development of Targeted Small Molecule Therapeutics for Oncology”

  • Professor Dean Felsher (Stanford University): “Reversing Cancer
    through Targeted Oncogene Inactivation”

  • Alexander “Sasha” Kamb, Ph.D. (Neuroscience Therapeutic Area Head,
    Amgen): “Problems and (Possible) Solutions in the Neurosciences
    Therapeutic Area”

Session on China Biotechnology and Drug Development

  • Joseph McCracken, Ph.D. (Vice President, Business Development,
    Genentech): “Collaboration: a key to Genentech’s success as the
    leading biotechnology company”

  • Wayne Li, Ph.D. (Morningside Group): “The State and Future of
    Biotech Funding in China”

  • Jing-shan Hu, Ph.D. (Director, Licensing, Merck): “Maintaining a
    Competitive Edge in a Changing Landscape”

  • Jintao Zhang, Ph.D. (President, Shanghai Medicilon): “The CRO
    Business in China Today and Tomorrow”

  • Tony Zhang, Ph.D. (Managing Director and site head, China R&D, Eli
    Lilly): “Pharmaceutical R&D Networks and NME Development Efficiency”

  • Yingfei Wei, Ph.D. (Chief Scientific Officer, 3SBio): “Biosimilars
    in China: Current State and Future”

  • Allan Riting Liu, Ph.D. (Shanghai Fosun Pharmaceutical Group):
    “Fosun Pharma and Its Licensing and R&D Alliance Strategy”

Expert Forum & Panel Discussion on Trends in Biotechnology
and Entrepreneurship

  • Mini Keynote: Brian Cunningham, J.D. (Senior Counsel and Co-Chair
    of the Life Science Group, Morrison & Foerster): “Perspective on
    Today’s BioPharmaceutical Environment”

  • Distinguished Panelists: Jin-Long Chen, Ph.D. (CEO, NGM Biopharmaceuticals); Cheni Kwok, Ph.D. 
    (Senior Vice President, Poniard
    Pharmaceuticals);  Larry Wang, Ph.D. (President, GenScript); Alex Wu, Ph.D. (CEO,
    Crown BioScience)

Major Sponsors’ Presentations:

  • Taicang Science Park

  • Zhangjiang Biotech & Pharma Base

  • GenScript

  • AzoPharma

  • Pharmaron